Core Insights - The company reported interim results for the six months ending June 30, 2025, achieving revenue of 13.426 million RMB, compared to no revenue in the same period last year [1] - Gross profit for the period was 11.827 million RMB, also compared to no gross profit in the previous year [1] - Research and development expenses amounted to 88.885 million RMB [1] Revenue Drivers - The revenue growth is primarily attributed to the commercialization of the company's interventional products for treating structural heart diseases, leading to an increase in sales volume [1] Product Development - In the first half of 2025, the company made significant progress in its product pipeline for treating tricuspid, aortic, and mitral valve diseases, resulting in a diversified and high-potential product portfolio [1] International Expansion - The company is actively enhancing its international business layout to increase product influence and clinical application scale, laying a solid foundation for long-term high-speed growth [1]
持续加大国际化业务布局力度 健世科技-B发布中期业绩 毛利1182.7万元